NEWARK, N.J. , Sept.
19, 2024 /PRNewswire/ -- BioCentriq , a leading cell therapy contract development and manufacturing organization (CDMO), today announces that it has appointed Syed T. Husain as its new Chief Executive Officer (CEO), and as a member of the Board of Directors. BioCentriq has selected Syed for his extensive expertise in CDMO development and manufacturing services, with a deep understanding of the cell and gene therapy supply and value chains.
His experience spans the entire drug development and commercialization lifecycle, including over 20 years of strategic management, leading companies through rapid growth, go-to-market innovation, and industry disruption. BioCentriq now has a CEO with a proven track record in creating global business development strategies, enhancing market and brand presence, building high-performing teams, implementing operational improvements, increasing financial returns, and providing strategic leadership to drive patient focus and profitable revenue growth. "The cell and gene therapy (CGT) sector has reached a new stage, where a range of late-stage therapies are reaching commercialization, and a considerable number of next-generation therapies are entering and progressing through early-stage clinical development.
In turn, the cell and gene therapy sector is meeting strong pressures on investment required for high costs of development and product manufacturing, in turn increasing pressure on the pricing for commercialized therapies..